Clinical Trials
- A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) sponsored by Synta Pharmaceuticals Corp
- Synta Pharmaceuticals Initiates Phase 2 Clinical Trial of STA-9090 in Gastrointestinal Stromal Tumors (GIST) following failure of Gleevec® and Sutent® STA-9090 shows encouraging preclinical and clinical results in GIST
- STA-9090 Hsp90 Inhibitor,Phase I -http://tinyurl.com/yc6gjge
- Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. Rink L, Skorobogatko Y, Kossenkov AV, Belinsky MG, Pajak T, Blanke CD, von Mehren M, Ochs MF, Eisenberg B, Godwin AK. Mol Cancer Ther. 2009 Aug;8(8):2172-82. Epub 2009 Aug 11. PMID: 19671739 [PubMed - in process] Related Articles
- High density DNA array analysis reveals distinct genomic profiles in a subset of gastrointestinal stromal tumors. Belinsky MG, Skorobogatko YV, Rink L, Pei J, Cai KQ, Vanderveer LA, Riddell D, Merkel E, Tarn C, Eisenberg BL, von Mehren M, Testa JR, Godwin AK. Genes Chromosomes Cancer. 2009 Oct;48(10):886-96. PMID: 19585585 [PubMed - in process] Related Articles
- Phase I study of BIIB028 sponsored by Pharmaceutical Comp. Biogen Idec.
- Two Phase III Clinical Trials for Front Line Therapy in Gist
- Phase III, Open-label Study of Nilotinib Versus Imatinib in GIST Patients
- Efficacy and Safety of Masitinib (AB1010) in Comparison to Imatinib in Patients With Gastro-intestinal Stromal Tumour
- Search for a GIST clinical trial at cancer.gov
- Click here for more GIST clinical trials seeking volunteers at clinicaltrials.gov
20 open trials dating back 180 days from clinicaltrials.gov:
Novartis Nilotinib
Compassionate Use (CU) Program
Patients who are not able to participate in ongoing nilotinib clinical trials may be able to receive nilotinib on a compassionate use basis.
Requests for compassionate use will only be considered when the request is sent to Novartis by the treating physician through a secure, business email.
Patients will be evaluated for eligibility based on pre-defined inclusion/exclusion criteria.
Requests should be routed to the local, country Novartis medical representative for submission to the following email address:
-
Gallery
